# Re-evaluation Task: LUN-002

## Context
- **Case ID**: LUN-002
- **Cancer type**: Non-Small Cell Lung Cancer — Squamous Cell Carcinoma
- **Stage**: Stage II
- **Molecular profile**: PD-L1 TPS 1-49%, FGFR1 amplified
- **Report file**: experiment_reports\LUN-002_report.json
- **Current score**: 85/100
- **Gap analysis (local GPU)**: The most critical gaps in LUN-002 include the lack of data on Perioperative Nivolumab + Platinum-Based Chemotherapy and Adjuvant Pembrolizumab Post-Surgery and Chemotherapy, as these combinations are crucial for understanding the efficacy of immunotherapies in surgical settings. Filling these gaps will improve the score by providing more comprehensive insights into the effectiveness of these treatments, which are essential for optimizing patient outcomes and informing future clinical trials.

## Current dimension scores
| Dimension | Score | % of max |
|---|---|---|
| evidence_depth                      |  13/25  |  52.0% |
| rating_calibration                  |  13/15  |  86.7% |
| clinical_relevance                  |   9/10  |  90.0% |
| structural_integrity                |  15/15  | 100.0% |
| tier_coverage                       |  10/10  | 100.0% |
| source_quality                      |  15/15  | 100.0% |
| combo_supportive_coverage           |  10/10  | 100.0% |

## Target dimension: `evidence_depth` (52.0% of max)

## Your instructions

Read the full report JSON at `experiment_reports\LUN-002_report.json`.

Your task: Fill missing evidence fields in `treatments[].key_evidence`.

For each treatment where these are null or missing, search and fill:
- `key_evidence.study_name` — full trial name
- `key_evidence.year` — publication year
- `key_evidence.sample_size` — numeric patient count
- `key_evidence.os_months.treatment` — median OS in treatment arm (months)
- `key_evidence.os_months.control` — median OS in control arm (months)
- `key_evidence.os_months.hazard_ratio` — HR from primary analysis
- `key_evidence.os_months.p_value` — p-value from OS analysis
- `key_evidence.pfs_months.treatment` — median PFS treatment arm
- `key_evidence.pfs_months.control` — median PFS control arm

Rules:
- Only fill with data you can verify from published trials
- Set to null (not omit) if genuinely unavailable after searching
- Do NOT fabricate or estimate numbers

Return the corrected `treatments` array only.

## Output format

Return a valid JSON object containing ONLY the corrected section (e.g., `{"treatments": [...]}` or `{"sources": [...]}`).

Do NOT return the full report — only the corrected array. The runner will merge it back.

After returning the JSON, add one line:
`SCORE_IMPACT: <estimated new score>/100`

## Report JSON (for reference)

```json
{
  "report_metadata": {
    "generated_date": "2026-03-23",
    "cancer_type": "Non-Small Cell Lung Cancer — Squamous Cell Carcinoma",
    "stage": "Stage II",
    "molecular_profile": [
      "PD-L1 TPS 1-49%",
      "FGFR1 amplified"
    ],
    "patient_info": {
      "age": 45,
      "sex": "Male",
      "ecog_performance_status": 0,
      "risk_factors": [
        "Heavy alcohol use"
      ],
      "comorbidities": [
        "Hypertension"
      ]
    },
    "case_id": "LUN-002"
  },
  "treatments": [
    {
      "rank": 1,
      "name": "Surgical Resection (Lobectomy) + Adjuvant Cisplatin-Vinorelbine Chemotherapy",
      "category": "Standard of Care",
      "composite_rating": 8.9,
      "rating_breakdown": {
        "evidence_level": {
          "score": 10,
          "rationale": "Phase 3 RCTs (JBR-10, ANITA) and LACE meta-analysis of 4,584 patients demonstrate clear survival benefit for adjuvant cisplatin-vinorelbine in completely resected stage II NSCLC"
        },
        "survival_benefit": {
          "score": 8,
          "rationale": "LACE meta-analysis showed 11.6% absolute 5-year survival improvement for stage II NSCLC with cisplatin-vinorelbine (HR 0.80, 95% CI 0.70-0.91, p<0.001). 5-year OS for stage II is approximately 60-65% with surgery plus adjuvant chemo"
        },
        "accessibility": {
          "score": 10,
          "rationale": "FDA-approved, NCCN Category 1 recommendation, universally available at all cancer treatment centers worldwide"
        },
        "safety_profile": {
          "score": 7,
          "rationale": "Well-characterized toxicity profile. Grade 3/4 neutropenia is common (~73%). Cisplatin causes nephrotoxicity, ototoxicity, nausea. Heavy alcohol use may increase hepatotoxicity risk requiring close liver function monitoring"
        },
        "biomarker_match": {
          "score": 10,
          "rationale": "No biomarker requirement — universally applicable to all resectable stage II NSCLC regardless of PD-L1 or FGFR1 status"
        }
      },
      "mechanism_of_action": "Lobectomy removes the primary tumor with adequate margins. Cisplatin cross-links DNA causing apoptosis; vinorelbine inhibits microtubule assembly blocking mitosis. Together they eliminate micrometastatic disease post-resection.",
      "key_evidence": {
        "study_name": "LACE Meta-Analysis (Cisplatin-Vinorelbine Subgroup)",
        "journal": "Journal of Clinical Oncology",
        "year": 2010,
        "sample_size": 1888,
        "os_months": {
          "treatment": 0,
          "control": 0,
          "hazard_ratio": 0.8,
          "p_value": 0.001
        },
        "pfs_months": {
          "treatment": 0,
          "control": 0
        },
        "orr_percent": {
          "treatment": 0,
          "control": 0
        }
      },
      "biomarker_requirements": [],
      "notable_side_effects": [
        "Grade 3/4 neutropenia (~73%)",
        "Cisplatin-induced nephrotoxicity",
        "Cisplatin-induced ototox
... (truncated — read full file from experiment_reports\LUN-002_report.json)
```
